Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ketoconazole
Drug ID BADD_D01230
Description Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981.[A188054] At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue to be used in topical formulations.
Indications and Usage Ketoconazole is used in the treatment or prevention of fungal infections including blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis.[FDA Label] In Europe, it is also used in the treatment of endogenous Cushing's syndrome.[L7736]
Marketing Status approved; investigational
ATC Code D01AC08; G01AF11; H02CA03; J02AB02
DrugBank ID DB01026
KEGG ID D00351
MeSH ID D007654
PubChem ID 3823
TTD Drug ID D0B4IF
NDC Product Code 60524-000; 62991-1461; 63629-8677; 68788-8257; 51927-0065; 52286-0009; 35573-433; 43538-531; 50090-6142; 63629-8675; 63629-8819; 70518-0915; 72789-052; 53002-8151; 63629-8820; 71205-105; 68071-2902; 70518-3367; 71085-008; 72189-428; 58159-091; 50090-0720; 51672-1298; 53002-8150; 68071-2309; 59349-0001; 0093-3219; 45802-465; 50090-6069; 63629-8676; 63646-010; 70518-2831; 72189-180; 51407-279; 55505-192; 63187-774; 68788-7755; 49452-3913; 66478-0145; 16714-955; 43538-530; 45802-532; 66267-400; 71713-097; 38779-0279; 53069-0390; 0168-0099; 51672-4026; 64380-827; 68788-9903; 71335-1849; 65085-0028; 50090-5265; 51552-0627; 51927-3194; 68981-023; 55505-196; 60429-020
UNII R9400W927I
Synonyms Ketoconazole | R-41400 | R 41400 | R41400 | R41,400 | Nizoral
Chemical Information
Molecular Formula C26H28Cl2N4O4
CAS Registry Number 65277-42-1
SMILES CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Condition aggravated08.01.03.0040.000323%Not Available
Constipation07.02.02.001--
Cushing's syndrome19.07.03.002; 14.11.01.007; 05.01.01.001; 24.08.04.0010.000132%Not Available
Dandruff23.03.16.001--Not Available
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.002--
Dermatitis contact23.03.04.004; 12.03.01.040; 10.01.01.003--Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.0030.000804%
Drug eruption10.01.01.005; 23.03.05.001; 08.01.06.0150.000066%Not Available
Drug hypersensitivity10.01.01.0010.000850%Not Available
Drug ineffective08.06.01.0060.001688%Not Available
Drug interaction08.06.03.0010.002927%Not Available
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Dysgeusia17.02.07.003; 07.14.03.0010.000145%
Dyspepsia07.01.02.001--
Eczema23.03.04.0060.000132%
Electrocardiogram QT prolonged13.14.05.004--
Endocrine disorder05.09.01.001--Not Available
Epistaxis24.07.01.005; 22.04.03.0010.000145%
Erythema23.03.06.0010.000547%Not Available
Erythema multiforme10.01.03.015; 23.03.01.003--
Eye disorder06.08.03.001--Not Available
Eye irritation06.04.05.003--Not Available
Eye pain06.08.03.0020.000145%
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene